TGTX Operating Cycle from 2010 to 2026
| TGTX Stock | USD 28.86 1.10 3.96% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 1.1 K | Current Value 1 K | Quarterly Volatility 14.1 K |
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 338.1 K, Interest Expense of 29 M or Total Revenue of 397.3 M, as well as many indicators such as Price To Sales Ratio of 11.37, Dividend Yield of 4.0E-4 or PTB Ratio of 18.59. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
TGTX | Operating Cycle | Build AI portfolio with TGTX Stock |
The evolution of Operating Cycle for TG Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how TG Therapeutics compares to historical norms and industry peers.
Latest TG Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of TG Therapeutics over the last few years. It is TG Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
TGTX Operating Cycle Regression Statistics
| Arithmetic Mean | 6,774 | |
| Geometric Mean | 551.06 | |
| Coefficient Of Variation | 208.25 | |
| Mean Deviation | 10,379 | |
| Median | 445.58 | |
| Standard Deviation | 14,108 | |
| Sample Variance | 199M | |
| Range | 40.4K | |
| R-Value | (0.06) | |
| Mean Square Error | 211.5M | |
| R-Squared | 0 | |
| Significance | 0.81 | |
| Slope | (174.62) | |
| Total Sum of Squares | 3.2B |
TGTX Operating Cycle History
About TG Therapeutics Financial Statements
TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 1.1 K | 1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.